Die schöne PRANA

Bist noch drin? Habe mir heute eine kleine Position gegönnt. Das scheint hier sehr erfolgversprechend zu sein.
Der Alzheimerspezialist mit einer MK gerade mal von 285 Mio USD läuft doch noch bis mindestens 500.Nach dann, viel Erfolg allen Investierten!  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.01.14      6,26      6,40§6,251 6,34 $ 183.177 1,13 M
  14.01.14      6,29      6,47§6,02 6,27 $ 316.066 1,95 M
  13.01.14      6,05      6,50§6,01 6,22 $ 568.481 3,46 M
  10.01.14      6,02      6,47§6,02 6,28 $ 537.849 3,31 M
  09.01.14      6,28      6,28§5,86 6,02 $ 593.139 3,49 M
  08.01.14      6,13      6,31§6,10 6,24 $ 330.737 2,02 M
  07.01.14      6,01      6,36§5,83 6,22 $ 1.188.693 6,94 M
  06.01.14      6,80    6,8199§6,23 6,27 $ 1.051.681 6,71 M
  03.01.14      7,05      7,05§6,86 6,99 $ 218.326 1,49 M
  02.01.14      6,99      7,15§6,85 7,03 $ 283.638 1,95 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  17.01.14      6,94    7,4435§6,75 7,10 $ 952.413 6,64 M

GrB  

PRANA BIOTECHNOLOGY LTD Aktie
WKN: 753907 Symbol: PRAN Typ: Aktie
SK 7,10 $ SKP +0,00 Pott +55,34%

buran und MfG und schüddelböööööön
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
  31.01.14     11,40     13,15§11,10 11,60 $ 2.613.706 31,0 M
  30.01.14     10,65     13,29§9,91 12,33 $ 5.387.732 60,7 M
  29.01.14      9,82     10,89§9,41 10,23 $ 1.734.176 17,5 M
  28.01.14      9,83     10,25§9,01 9,96 $ 1.806.275 16,7 M
  27.01.14      9,25      9,85§9,15 9,69 $ 1.583.282 14,7 M
  24.01.14      8,50      9,15§8,40 8,99 $ 1.188.863 10,1 M
  23.01.14      8,65      8,99§8,03 8,85 $ 1.148.128 9,40 M
  22.01.14      8,56      8,90§8,18 8,66 $ 1.769.529 14,8 M
  21.01.14      7,20      8,74§7,20 8,28 $ 1.984.988 15,5 M
  17.01.14      6,94    7,4435§6,75 7,10 $ 952.413 6,64 M
  16.01.14      6,24      7,09§6,20 6,93 $ 751.323 5,00 M
  15.01.14      6,26      6,40§6,251 6,34 $ 183.177 1,13 M
  14.01.14      6,29      6,47§6,02 6,27 $ 316.066 1,95 M
  13.01.14      6,05      6,50§6,01 6,22 $ 568.481 3,46 M
  10.01.14      6,02      6,47§6,02 6,28 $ 537.849 3,31 M
  09.01.14      6,28      6,28§5,86 6,02 $ 593.139 3,49 M
  08.01.14      6,13      6,31§6,10 6,24 $ 330.737 2,02 M
  07.01.14      6,01      6,36§5,83 6,22 $ 1.188.693 6,94 M
  06.01.14      6,80    6,8199§6,23 6,27 $ 1.051.681 6,71 M
  03.01.14      7,05      7,05§6,86 6,99 $ 218.326 1,49 M
  02.01.14      6,99      7,15§6,85 7,03 $ 283.638 1,95 M

GrB  

Was war das denn zum Schluss? Oder man ist eben schon verwöhnt. Waren sehr gute Tage!  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.02.14     11,89     12,12§10,65 10,88 $ 1.086.354 12,0 M

GrB  

Prana Biotechnology Ltd Could Be Big Movers in Healthcare Todayhttp://www.fool.com/investing/general/2014/01/31/...nc-and-prana.aspx
 

Jan. 24 to Jan. 31
Comment NowFollow Comments
These are the best and worst-performing medical and biotech stocks from Jan. 24 to Jan. 31, a period during which the American Stock Exchange’s Biotechnology Index r0se 0.4%. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations of more than $300 million at the beginning of the week. The data come from Interactive Data and Thomson Reuters Fundamentals via FactSet Research Systems.http://www.forbes.com/sites/matthewherper/2014/02/...partner=yahootix  

It Sounds
Feb. 3, 2014 9:12 AM ET | http://seekingalpha.com/article/...icious-than-it-sounds?source=yahoo  

Number of Tickers: 245
Date: 6-Feb-14
Contributor:§ValuEngine, Inc.
    Title:§ValuEngine Industry Report for Medical-biomed/genetics
Document Size: 18 pages
Price: $49
Document Type: Adobe Acrobat Reader®
Download free Adobe Acrobat Reader®
http://reports.finance.yahoo.com/w0?r=50217056:1  

SK 10,88 $ SKP -7,40 Pott +137,08% buran und MfG und danke und Die schöne PRANA


 

Top!! Bist heut bisschen aufgestiegen;-) n'kleines bisschen!
Wer den Aktien ab und an mal Komplimente macht, dann siehsts so aus wie Hier!
Was meinste? Wieviel ist hier noch möglich?  

Die müsste wohl nachziehen, oder lieg ich da falsch?  

Kann mir evtl. jemand den unterschied zwischen Prana 937103 und Prana 753907 erkären?
Finde zu WKN 937103 nirgends ein Info.
Danke  

Das sind im Grunde die gleichen, nur für den Amerikanischen Handel in Verhäntnis 10:1

Viele Firmen machen das so, zb. Vestas Windsystem da ist das Verhältnis 3:1

Solche Aktien erkennt an deren Endungszusatz

Ltd.Shares = Firmenanteile

Spon         = gesplittet  

Clinical Study of PBT2 for Treating Huntington Disease
12:05 18.02.14

PR Newswire

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014 /PRNewswire/ --

Key Points:

Primary endpoints of safety and tolerability met.
Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042).
PBT2 250mg was also associated with a favourable signal in functional capacity.  
Preliminary evidence suggests PBT2 250mg reduced atrophy of brain tissue in areas affected in Huntington disease, seen in a pilot imaging sub-study.
Company plans to advance PBT2 to a confirmatory Phase 3 clinical trial.
Prana to host investor conference call and webcast today at 5:30pm ET; See access information below
Prana Biotechnology(ASX:PBT; NASDAQ:PRAN) today announced that its Phase 2 REACH2HD clinical trial investigating PBT2 as a treatment for Huntington disease met its primary safety endpoint and achieved statistically significant improvement in a measure of executive function (cognition), which comprised part of the study's main efficacy outcome. Prana plans to advance PBT2 into a confirmatory Phase 3 clinical trial that could allow PBT2 to be approved for the treatment of Huntington disease.

Dr. Ray Dorsey, Professor of Neurology at the University of Rochester and the Principal Investigator on the trial added: "We are very pleased that the results of the Reach2HD study have shown that PBT2 is well tolerated and generally safe over six months in individuals with early to mid-stage Huntington disease."

"In addition, the results indicated a significant benefit on cognition that is consistent with the previous trial in Alzheimer's disease and is accompanied by an encouraging finding in functional capacity. We are very thankful for the involvement of the research participants and investigators in this study and look forward to future trials of this promising therapy for one of the cardinal features of Huntington disease."

Reach2HD is a double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia. The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.

The primary endpoint of the study was met. In this study, PBT2 was safe and well tolerated. Ninety-five percent (104 of 109) of participants completed the study on their assigned dose. There were no substantial differences in adverse events across the two PBT2 dose groups and the placebo group. Only one of the ten reported serious adverse events was deemed by the clinical site investigator to be related to drug treatment.

An independent Data Safety Monitoring Board met on five occasions over the course of the trial and on each occasion recommended that the trial continue as per the original protocol.

The effects of PBT2 were tested on cognition, motor performance, behaviour and functional capacity, of which cognition was pre-specified as the main efficacy outcome.

There was a statistically significant improvement in performance on the Trail Making Test Part B, in the PBT2 250mg group compared to placebo at both 12 (p<0.001) and 26 weeks (p=0.042). Trail Making Test Part B is a measure of executive function (e.g., ability to plan activities), which is impaired early in the course of Huntington disease and is also affected in Alzheimer's disease.

Given the evidence from an earlier trial that showed that PBT2 improved executive function in Alzheimer's disease patients, the Reach2HD trial included a plan to assess the effects of PBT2 on an Executive Function Composite z-score that included the Trail Making Test Part B. There was a statistically significant improvement in this z-score (p=0.038) in a pre-specified analysis of Reach2HD participants with early stage Huntington disease, as measured by their Total Functioning Capacity score. Across all participants, which comprised both early and mid-stage patients, there was a trend to improvement (p=0.069).

Dr. Rudy Tanzi, Professor of Neurology at Harvard Medical School and Prana's Chief Scientific Advisor, said: "The observation of significant improvement in executive function with PBT2 in this clinical trial for Huntington disease and the previously reported Alzheimer's trial, suggests a common mechanism for neurodegeneration in these diseases based on metal interactions. In my opinion, these findings significantly elevate the potential for PBT2 as an effective therapy for both Huntington disease and Alzheimer's disease."

The improvement in executive function was accompanied by a small but favourable signal in a key measure of functional capacity.

Dr. Ira Shoulson, Professor of Neurology at Georgetown University and Chair of the Huntington Study Group, who was not involved in the trial and acts as an advisor to Prana, added: "In the Reach2HD trial, the improvement in executive function performance was also accompanied by a favourable signal of a slowing of functional decline, as measured by the Total Functional Capacity score. This is the first time we have observed dose-related slowing in functional decline over a six month period of treatment – which taken together with the safety reassurance –  will provide genuine optimism for the Huntington disease community to support a larger confirmatory trial of PBT2 in Huntington disease."

Finally, as Huntington disease and other neurodegenerative disorders progress, there is a gradual loss of brain tissue or atrophy. In Reach2HD, brain imaging using magnetic resonance imaging (MRI) was performed in a small subset of patients (n=6) to map anatomical changes in brain structure. In the combined PBT2 groups (n=4) a reduction in atrophy  of brain tissue in regions of the brain known to be affected by Huntington disease was observed compared to the placebo group.

Dr. Diana Rosas, Associate Professor of Neurology at Harvard Medical School and the study's co-Principal Investigator who conducted the imaging sub-study commented: "Despite the very small number of patients in the sub-study, the data are suggestive of a beneficial effect of PBT2 in regions of the brain that are known to be vulnerable to Huntington disease."

A detailed clinical announcement is available on the Company's web site at www.pranabio.com. For patient enquiries please contact huntingtons@pranabio.com or call 1300 13 90 33.

Investor Conference Call Information:

Prana will host an investor conference call and webcast this evening at 5:30pm Eastern Time to discuss the study results.  Investors in the United States may access the conference call by dialing 1 (855) 293-1544; conference ID: 58817510.  The live webcast may be accessed here.  Additional conference call information is available at www.pranabio.com, including Australian and international conference numbers.

Due to the expected high number of participants on the call, we recommend you commence registration for the event 15 minutes prior.   A recording of the call will be available within 4 hours of its conclusion and will remain available for three months.  The archived recording can be accessed here.

Contacts:



Global Investor Relations Lead

Rebecca Wilson

T: +61 3 8866 1216

E: rwilson@buchanwe.com.au

Investor Relations (USA)

Joshua Drumm

T: +1 (212) 375-2664

E: jdrumm@tiberend.com






Media Relations (Australia)

Ben Oliver

T: +61 3 8866 1233

E: boliver@buchanwe.com.au

Media Relations (US)

Andrew Mielach

T: +1 (212) 375-2694

E: amielach@tiberend.com





SOURCE Tiberend Strategic Advisors, Inc.


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  28.02.14     11,62     12,22§10,50 11,31 $ 2.513.360 28,3 M
  27.02.14     11,12     11,68§10,95 11,53 $ 2.037.456 22,0 M
  26.02.14     10,36     12,08§10,31 11,227 $ 8.295.102 92,6 M
  25.02.14      8,78      9,74§8,78 9,36 $ 2.532.113 23,3 M
  24.02.14      8,39      9,36§8,36 9,03 $ 3.901.244 34,1 M
  21.02.14      7,95      8,49§7,60 8,03 $ 3.865.437 29,9 M
  20.02.14      8,36      8,87§8,01 8,07 $ 4.571.578 36,8 M
  19.02.14    9,8924     10,15§8,71 8,76 $ 8.381.777 76,5 M
  18.02.14      8,31     10,74§7,80 10,10 $ 23.864.327 225 M
  14.02.14      8,00      8,07§7,08 7,25 $ 2.422.624 17,5 M
  13.02.14      7,89      8,78§7,89 8,14 $ 1.374.408 11,2 M
  12.02.14      8,69      8,74§7,90 8,03 $ 1.980.311 15,8 M
  11.02.14      9,33      9,55§8,55 8,69 $ 1.415.328 12,4 M
  10.02.14      9,35      9,73§8,26 9,14 $ 3.793.439 32,6 M
  07.02.14     10,40     10,93§9,51 9,92 $ 1.999.607 19,8 M
  06.02.14     11,89     12,12§10,65 10,88 $ 1.086.354 12,0 M
  05.02.14     11,74   12,3199§11,35 11,75 $ 814.071 9,21 M
  04.02.14     11,50     12,50§11,41 11,77 $ 1.329.920 15,3 M
  03.02.14     11,28     11,85§10,46 11,24 $ 1.709.203 18,5 M

buran und MfG und danke und weitermachen  

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 7,483 8,15 7,483  8,15 € 1.000 8.150

buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 11,07 11,44 10,73  10,79 $ 1.635.882 17,7 M

buran und MfG und danke und weitermachen und TOP  

of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease
13:10 31.03.14

PR Newswire

MELBOURNE, Australia, March 31, 2014

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology(ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well.

Commenting on the result, Geoffrey Kempler, CEO of Prana Biotechnology said: "This is the first time that Prana has looked at PiB-PET in a study with PBT2 to measure its effect on insoluble amyloid plaques. In our previous Alzheimer's study (EURO)1, we looked at levels of unaggregated soluble Abeta peptides in spinal fluid, and they were significantly reduced with PBT2 treatment. So in the IMAGINE trial we looked for an impact on the insoluble plaques as well, but did not see it differ significantly from the placebo."

"It is possible the result may point to PBT2 targeting soluble species of Abeta including toxic oligomers rather than plaques. Abeta oligomers are not visible in the PiB-PET scans which can only detect amyloid plaques. Alternatively, what we are seeing is simply the result of an inconclusive imaging readout in a small sample size with 42 participants (15 on Placebo, 27 on PBT2)".

No improvement was observed on the secondary endpoints of brain metabolic activity, cognition and function; however there was a trend towards preserving hippocampal brain volume in the PBT2 group.  Specifically, there was less atrophy in those patients treated with PBT2 relative to placebo, 2.6% and 4.0%, respectively.  This is consistent with published measures of atrophy in AD patients versus healthy controls2 of 4.7% and 1.4%, respectively. The company is tracking measures of brain volume and cognition in the current 12 month extension study that will be completed at the end of the year. Further analysis of the results is ongoing.

Importantly, PBT2 was shown to be safe and very well tolerated over the 52 weeks. The adverse event profile was equivalent between placebo and treated groups. Forty of the 42 enrolled participants (95%) completed the 52 week treatment period.

Mr. Kempler concluded: "Whilst not meeting all of our hopes, this result does not deter us from the future development of PBT2, a safe and well tolerated drug candidate for Alzheimer's disease. Our scientists and those from other institutes have developed a strong body of evidence for the efficacy of PBT2 in Alzheimer's disease. The suggestion of beneficial effect of PBT2 on brain volumes first seen in the Reach2HD Huntington disease trial and now in this Alzheimer's disease IMAGINE trial is intriguing. We are consulting with experts in the field to further assess these results and to consider how best to progress PBT2 in Alzheimer's disease. Indeed, the IMAGINE Extension trial is continuing, and data from this trial is likely to inform the next steps for an AD program."

Prana is proceeding with its plans toward a confirmatory study for Huntington disease.  Based on Prana's previous discussion with the US Food and Drug Administration, the data on safety and tolerability of PBT2 in Alzheimer's disease will support the future clinical development and, ultimately, a New Drug Application in Huntington disease.

Prana has a cash position of AU$25.4 million as at 31 March 2014.

1.  Lannfelt et al. Lancet Neurology (2008) vol. 7, pp. 779-86; Lannfelt et al. Lancet Neurology (2009) vol. 8, pp. 981.

2.  Barnes et al. Neurobiology of Aging (2009) 1711-1723

Investor conference call

Prana is hosting an investor conference call at 11.00pm Australian Eastern Daylight Savings time on Monday 31st March (8.00am USA EDT; 5.00am USA PDT, and 1.00pm UK BST).

The conference call will be recorded and available from 1am Australian EDST, Tuesday 1 April, at http://www.openbriefing.com/OB/1378.aspx

Conference ID: 693727



Australian Participation Dial-in-numbers

Toll: +61 2 9007 3187 (can be used if dialing from an international location)

Toll-free: 1800 558 698

Toll-free: 1800 809 971

International Participation Dial-in-numbers

Canada/USA Toll Free:                1855 881 1339

New York Local Number              208 758 0667

France Toll Free:                        0800 913 848

Germany Toll Free:                     0800 182 7617

Hong Kong Toll Free:                  800 966 806

New Zealand Toll Free:               0800 453 055

Singapore Toll Free:                   800 101 2785

South Africa Toll Free:                0800 999 976

Switzerland Toll Free:                 0800 820 030

United Kingdom Toll Free:           0800 051 8245

Contacts:



Global Investor Relations Lead                                

Investor Relations (USA)

Rebecca Wilson                                              

Joshua Drumm

T: +61 3 9866 4722                                          

T: +1 212-375-2664

E: rwilson@buchanwe.com.au                  

E: jdrumm@tiberend.com





Media Relations (Australia)                  

Media Relations (US)

Ben Oliver                                                          

Andrew Meilach

T: +61 3 9866 4722                                          

T: +1 212-375-2694

E: boliver@buchanwe.com.au                  

E: amielach@tiberend.com

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

About IMAGINE Phase II Clinical Trial for Alzheimer's Disease

A randomized placebo-controlled clinical study involving 42 patients (males and females over 44 years) with prodromal or mild Alzheimer's disease. Patients were randomized (ratio of 2:1) into either an active treatment group receiving 250mg PBT2 or placebo group over 52 weeks.  The primary objective was to evaluate brain amyloid levels by PiB PET imaging. The secondary objective was to evaluate the effect of PBT2 on safety and tolerability, brain metabolic activity, brain volumes and cognition, and functional abilities.    




Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other  risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Prana Biotechnology Limited


Quelle: PR Newswire  

Shoulson joins Prana Board
07:30 14.05.14

PR Newswire

MELBOURNE, Australia, May 14, 2014

MELBOURNE, Australia, May 14, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT, NASDAQ: PRAN) is pleased to announce Professor Ira Shoulson will join the Company's Board of Directors as a Non-Executive Director.

Professor Shoulson is one of the world's foremost experts in neurodegenerative diseases and movement disorders, and the founder of international academic consortia the Huntington Study Group and Parkinson Study Group, which have been instrumental in the development of innovative drugs to treat these disabling neurological conditions. This is his first company Board position.

Professor Shoulson is Professor of Neurology, Pharmacology and Human Science at Georgetown University, Washington, DC, USA, and Director of the University's Program for Regulatory Science and Medicine (PRSM). He is also principal investigator of the Georgetown University Center of Excellence in Regulatory Science and Innovation (CERSI), one of four research and education centers currently funded by the Food and Drug Administration (FDA).

Professor Shoulson has served as a consultant to, and member of, several FDA advisory committees over the past three decades, and has been involved in eight successful new drug applications to the FDA, notably long-acting methylphenidate (Concerta©) for attention deficit disorder, rasagiline (Azilect©) for Parkinson disease, and tetrabenazine (Xenazine©), the first drug approved by the FDA for the treatment of chorea in Huntington disease (HD).

Prana Biotechnology CEO and Executive Chairman Geoffrey Kempler said: "Professor Shoulson's clinical and regulatory experience will be pivotal as Prana prepares to meet with regulators later this year to chart the next steps in PBT2's development as a treatment for Huntington disease."

Professor Shoulson said joining the Prana board was an exceptional opportunity to help develop the next generation of treatments for neurodegenerative disorders.

"I have spent my entire professional life developing treatments aimed at making a difference for patients with Huntington disease, Parkinson disease and similar neurodegenerative disorders," he said.

"Based on the Reach2HD study and ongoing discovery and translational research, I believe PBT2 is among the most promising of experimental treatments intended to ameliorate the disabling cognitive impairment of HD, which is a major source of disability for our patients."

"Besides PBT2, Prana has an expanding library of compounds that are applicable not just to neurological disorders but other disorders including cancer."

Professor Shoulson's position as a non-Executive Director of Prana Biotechnology is effective immediately. Prior to taking up his position with Prana, Professor Shoulson concluded his elected term as Chair and President of the Huntington Study Group.

Contacts:







Investor Relations          

Media Relations

Rebecca Wilson            

Ben Oliver                        

T: +61 3 8866 1216        

T: +61 3 8866 1233          

E: rwilson@buchanwe.com.au    

E: boliver@buchanwe.com.au                  

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease, Huntington disease and other neurodegenerative and movement disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other  risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SOURCE Prana Biotechnology


Quelle: PR Newswire  

Wenn man das US Board liest könnte es hier abgehen. Bin ich gespannt mit meinem Long Investment.

Nur meine Meinung, keine Kauf- oder Verkaufsempfehlung.  

http://www.nasdaq.com/symbol/pran/premarket

Pre 50000 Stk a 2.12 :-)  

http://www.nasdaq.com/symbol/pran/real-time

Ist was im Busch?